story of the week
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Patients With Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
JAMA Oncol 2020 Jul 16;[EPub Ahead of Print], I Puzanov, A Ribas, C Robert, J Schachter, M Nyakas, A Daud, A Arance, MS Carlino, SJ O'Day, GV Long, KA Margolin, R Dummer, D Schadendorf, J Lutzky, PA Ascierto, A Tarhini, J Lin, R Mogg, B Homet Moreno, N Ibrahim, O HamidFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.